feed,title,long_url,short_url
Benzinga,KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrated Superior Progression-Free Survival (PFS) and Overall Survival (OS) Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma,https://www.benzinga.com/pressreleases/21/02/b19655138/keytruda-pembrolizumab-plus-lenvima-lenvatinib-demonstrated-superior-progression-free-survival-pfs,https://j.mp/3u46z8b
Benzinga,"Midsize Sedans Available at Cocoa Hyundai, Research on Dealer Website",https://www.benzinga.com/pressreleases/21/02/n19655135/midsize-sedans-available-at-cocoa-hyundai-research-on-dealer-website,https://j.mp/2OC5mof
Benzinga,2021 Hyundai Venue and Other Crossovers Available at Coastal Hyundai,https://www.benzinga.com/pressreleases/21/02/n19655134/2021-hyundai-venue-and-other-crossovers-available-at-coastal-hyundai,https://j.mp/3qkAUgb
Benzinga,Exelixis Highlights Positive Results for CABOMETYX® (cabozantinib) in Patients with Metastatic Papillary Renal Cell Carcinoma in SWOG S1500/PAPMET Study at ASCO GU,https://www.benzinga.com/pressreleases/21/02/b19655131/exelixis-highlights-positive-results-for-cabometyx-cabozantinib-in-patients-with-metastatic-papill,https://j.mp/3d9CVYO
